Gene Variant Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Gene ERBB2
Variant exon20
Impact List unknown
Protein Effect unknown
Gene Variant Descriptions ERBB2 (HER2) exon 20 indicates an unspecified mutation has occurred in exon 20 of the ERBB2 (HER2) gene.
Associated Drug Resistance

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

No Variant Reference Transcript is Available.
No transcript is Available.

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Protein Effect Treatment Approaches
ERBB2 exon20 unknown
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
ERBB2 exon20 lung non-small cell carcinoma predicted - sensitive Pyrotinib Phase I Actionable In a Phase II trial, Pyrotinib treatment resulted in an objective response rate of 31.7% (19/60) in non-small cell lung cancer patients harboring ERBB2 (HER2) exon 20 mutations, with a median duration of response of 7.0 months and a median progression-free survival of 6.8 months (J Clin Oncol 37, 2019 (suppl; abstr 9089); NCT02834936). detail...
ERBB2 exon20 lung non-small cell carcinoma predicted - sensitive Pyrotinib Phase II Actionable In a Phase II trial, non-small cell lung cancer patients harboring an ERBB2 exon 20 mutation demonstrated an objective response rate of 53.3% (8/15) and a median progression-free survival of 6.4 months when treated with Pyrotinib (PMID: 30596880; NCT02535507). 30596880